{"id":62095,"date":"2025-09-19T08:09:12","date_gmt":"2025-09-19T12:09:12","guid":{"rendered":"https:\/\/www.rudebaguette.com\/?p=62095"},"modified":"2025-09-18T14:21:58","modified_gmt":"2025-09-18T18:21:58","slug":"elon-musks-terrifying-vision-12-lives-already-entrusted-to-me-sparks-urgent-debate-on-safety-and-innovation","status":"publish","type":"post","link":"https:\/\/www.rudebaguette.com\/en\/2025\/09\/elon-musks-terrifying-vision-12-lives-already-entrusted-to-me-sparks-urgent-debate-on-safety-and-innovation\/","title":{"rendered":"“My Brain Controls Computers Now”: Musk’s Secret Human Experiments That Terrify Scientists And Change Everything Forever"},"content":{"rendered":"
\n\n\n\n\n
IN A NUTSHELL<\/strong><\/td>\n<\/tr>\n
\n
    \n
  • \ud83e\udde0 Neuralink’s trials involve twelve participants<\/strong> globally, showcasing rapid expansion.<\/li>\n
  • \ud83d\udca1 The N1 implant has been used for over 2,000 days<\/strong> in total, indicating practical application.<\/li>\n
  • \ud83c\udf0d Trials have expanded beyond the U.S.<\/strong>, reflecting the technology’s global potential.<\/li>\n
  • \ud83d\udd0d Ethical implications and long-term effects of brain-computer interfaces remain key concerns<\/strong>.<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/figure>\n

    Neuralink, the brainchild of entrepreneur Elon Musk, has been making significant strides in the field of brain-computer interfaces. As of now, twelve individuals have had the revolutionary N1 brain implant, marking a substantial increase from the three participants recorded earlier this year. This rapid expansion of clinical trials, initiated after receiving FDA approval in 2024, highlights Neuralink’s commitment to advancing technology that could transform communication and interaction for people with severe paralysis. Moreover, the technology is not only being tested within the United States but is also expanding its reach internationally, showcasing the global potential of this innovation.<\/p>\n

    Neuralink’s Accelerated Clinical Trials<\/h2>\n

    Neuralink has made headlines with its swift progress in increasing the number of participants in its clinical trials. Initially, the trials began with only three individuals in February. By June, this number had more than doubled to seven. The latest updates reveal that five additional participants have been added, bringing the total to twelve. This rapid pace reflects Neuralink’s dedication to refining their technology and gathering data on its efficacy and safety.<\/p>\n

    The company emphasizes the importance of these trials as they aim to provide a groundbreaking solution for individuals suffering from severe paralysis. The N1 implant is designed to facilitate communication and interaction by establishing a direct interface between the human brain and digital devices. Such technology represents a significant leap forward in assistive technology, offering new possibilities for those with limited physical capabilities.<\/p>\n

    “She Just Typed with Her Mind” as Paralyzed Woman Uses Neuralink to Write Name and Sparks Explosive Battle Over Brain Chips and Human Augmentation Ethics<\/a><\/p><\/blockquote>\n